CAPTRUST Financial Advisors
ITRM

CAPTRUST Financial Advisors’s Iterum Therapeutics ITRM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-138,600
Closed -$4.16K – 3343
2026
Q1 		$4.16K Hold
138,600
– – ﹤0.01% 3008
2025
Q4 		$46.4K Buy
138,600
+27,000
+24% +$14.6K ﹤0.01% 2684
2025
Q3 		$74.8K Buy
111,600
+100,100
+870% +$78.4K ﹤0.01% 2534
2025
Q2 		$11.4K Buy
+11,500
New +$12K ﹤0.01% 2492
2022
Q3 		– Sell
-33
Closed – – 3056
2022
Q2 		$0 Hold
33
– – ﹤0.01% 5034
2022
Q1 		$0 Buy
+33
New +$191 ﹤0.01% 5021

Other funds holding ITRM

Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

CAPTRUST Financial Advisors's ITRM Position: Q2 2026 in Review

CAPTRUST Financial Advisors sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 138,600 shares — an estimated $4.16K sold.

CAPTRUST Financial Advisors first reported a position in ITRM in Q1 2022 and held it in 6 quarters. The position peaked at $74.8K in Q3 2025. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

  • CAPTRUST Financial Advisors reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 138,600 Iterum Therapeutics shares in Q2 2026, an estimated $4.16K.
  • CAPTRUST Financial Advisors first reported a position in Iterum Therapeutics in Q1 2022 and held it in 6 quarters.
  • CAPTRUST Financial Advisors's Iterum Therapeutics position peaked at $74.8K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.